Impact of partial reimbursement on hepatitis B antiviral utilization and adherence

Table 1 Patient characteristics before and after propensity score matching

	Before matching		After matching
	Cohort 1 (n = 14163)	Cohort 2 (n = 16228)	Cohort 1 (n = 13364)	Cohort 2 (n = 13364)
Age (mean ± SD)b	38.2 ± 12.6	39.6 ± 12.6	38.7 ± 12.6	38.9 ± 12.4
Male (%)b	67.7	64.7	66.7	66.5
Insurance type (%)b
Medical insurance	40.6	52.4	42.9	42.6
Out-of-pocket	58.2	47.0	56.3	56.6
Others	1.3	0.6	0.7	0.8
Disease statusb
Yes1	29.3%	23.6%	28.2%	27.9%

¹Having one of the following characteristics: (1) serum alanine aminotransferase (ALT) over two times upper limit of normal (ULN); (2) hepatitis B virus (HBV) DNA ≥ 20000 IU/mL for hepatitis B e antigen (HBeAg) (+) patients; or (3) HBV DNA ≥ 2000 IU/mL for HBeAg (-) patients. ANOVA was performed to compare age difference between cohort 1 vs cohort 2; χ² test was conducted to compare male (%), insurance type (%) and disease status between cohort 1 vs cohort 2.

^bP < 0.01, cohort 1 vs cohort 2.